Table A2.

Distribution of potentially inappropriate medications (PIMs) related to kidney failure depending on frailty.

	Nonfrail Patients (FRIED Score: 0 to 2) n = 22	Frail Patients (FRIED Score: 3 to 5) n = 44	Total
Number of patients for whom all treatments are adjusted to kidney function	8 (36.4%)	25 (56.8%)	33 (50%)
Number of patients with at least 1 PIMs related to renal failure	8 a (36.4%)	13 b (29.5%)	21 (31.8%)
Metformin	6 (27.3%)	12 (27.3%)	18 (27.3%)
Sitagliptin	3 (13.6%)	5 (11.4%)	8 (12.1%)
Acarbose	1 (4.5%)	0 (0%)	1 (1.5%)

^a 2 Nonfrail patients with 2 PIMs (overuse of metformin and sitagliptin); ^b 4 frail patients with 2 PIMs (overuse of metformin and sitagliptin). Dosage adjustments for patients with kidney failure (according to the Summaries of Product Characteristics available in 2016): Metformin: 1500 mg maximum per day if creatinine clearance is between 30 and 60 mL/min; contraindicated if creatinine clearance is <30 mL/ min). Sitagliptin: 50 mg maximum per day if creatinine clearance is between 30 and 50 mL/min; 25 mg maximum per day if creatinine clearance is <30 mL/ min). Acarbose: contraindicated if creatinine clearance is < 25 mL/min.